ArticleClinical research in cardiology : official journal of the German Cardiac Society2012
Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Cost-Effectiveness of Drug-Coated Balloons in the Treatment of Coronary Small Vessel Disease: A Report From the BASKET-SMALL 2 Randomized Controlled Trial.Journal of the American Heart Association · 2025Trial
- Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population.Arquivos brasileiros de cardiologia · 2017Article
- Improving 10-deacetylbaccatin III-10-β-O-acetyltransferase catalytic fitness for Taxol production.Nature communications · 2017Article
- Surrogate and clinical endpoints in interventional cardiology: are statistics the brakes?Therapeutic advances in cardiovascular disease · 2016Review
- Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Article
- Multifaceted prospects of nanocomposites for cardiovascular grafts and stents.International journal of nanomedicine · 2015Review
- Treatment of coronary de novo bifurcation lesions with DCB only strategy.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Drug-coated balloon therapy in coronary and peripheral artery disease.Nature reviews. Cardiology · 2014Review
- Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Review
- Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis.Clinical cardiology · 2013Article
- Cost-effectiveness of cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary artery disease in Germany.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have demonstrated the safety and efficacy of drug-coated balloon (DCB) angioplasty for the treatment of coronary in-stent restenosis (ISR). The cost-effectiveness of this practice is unknown.
methodsA Markov state-transition decision analytic model accounting for varying procedural efficacy rates, complication rates, and cost estimates was developed to compare DCB angioplasty with drug-eluting stent (DES) placement in patients with bare-metal stent (BMS)-ISR. Data on procedural outcomes associated with both treatment strategies were derived from the literature, and the cost analysis was conducted from a health care payer perspective. Effectiveness was expressed as life-years gained.
resultsIn the base-case analysis, initial procedure costs amounted to €3,604.14 for DCB angioplasty and to €3,309.66 for DES implantation. Over a 12-month time horizon, the DCB strategy was found to be less costly (€4,130.38 vs. €5,305.30) and slightly more effective in terms of life expectancy (0.983 vs. 0.976 years) than the DES strategy. Extensive sensitivity analyses indicated that, in comparison with DES implantation, the cost advantage of the DCB strategy was robust to clinically plausible variations in the values of key model input parameters. The variables with the greatest impact on base-case results were the duration of dual antiplatelet therapy with acetylsalicylic acid and clopidogrel after DCB angioplasty, the use of generic clopidogrel, and variations in the costs associated with the DCB device.
conclusionDCB angioplasty is a cost-effective treatment option for coronary BMS-ISR. The higher initial costs of DCB are more than offset by later cost-savings, predominantly as a result of reduced medication costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.